<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108651</url>
  </required_header>
  <id_info>
    <org_study_id>N201702069</org_study_id>
    <nct_id>NCT03108651</nct_id>
  </id_info>
  <brief_title>Mobile Motivational Messages for Change (3M4Chan) Intervention in TMU</brief_title>
  <official_title>Mobile Motivational Messages for Change (3M4Chan) Intervention in TMU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      About 100 (50 from TMU Hospital and 50 from Wellcome Clinic) current smokers will be
      recruited who contact smoke cession clinics in teaching hospitals of Taipei Medical
      University (TMU) and Wellcome Clinic. They will be randomly assigned either to Usual Care
      (UC) or Usual Care plus 3M4Chan Intervention group (IG). A randomized comparative
      effectiveness trial will be conducted. Patient will enroll from September 2017 to May 2018.
      In UC group, the physician provides a brief advice to quit during first consultation, a quit
      plan template, and medication prescription (Varenicline, Bupropion, Champix, Nicotinell
      TTS20) as decided by the physician. IG group includes UC plus a mobile App that is programmed
      to push tailored messages for health concern and readiness to quit, tips for sustaining
      abstinence, use of interactive self-assessments, helpful cessation information. This group of
      smokers will benefit from tailored cessation interventions with integrated body weight
      management elements that take into consideration the prevailing local and cultural influences
      on diet and levels of physical activity. IG will be continued even after stopping of the UC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention study with two parallel arms.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Researchers do not disclose about App and messages to control group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Smoking cessation rate at two months</measure>
    <time_frame>Up to 2 months</time_frame>
    <description>Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking cessation rate at four months</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Smoking cessation rate at six months</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>User engagement at an individual level</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Engagement at individual level will be assessed based on the rate of read messages by the patients. This is calculated as the quotient between the messages the patients have read, and the total number of messages the system has sent to the patients. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement at aggregated level - Mobile application rolling retention</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The percentage of users still active N days after installation. This is a ratio of the number of users whose last day of activity is past day N to the number of users who could have been active on day N. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement at aggregated level - Mobile application session length distribution</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The session length is defined as the length of time between the start of the application event and the end of the application event. The session length determines the engagement as it is relevant to know how much time patients spend in the app per session. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement at aggregated level - Mobile application session frequency</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The session frequency is a measure of how often each unique patient used the app within a given time interval. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement at aggregated level - Mobile application sessions per user</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>A session is one use of the mobile application by a patient. This begins when the application is launched and ends when the application is terminated. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engagement at aggregated level - Mobile application return rate</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Return rate measures the percentage of patients who return to the app on a specific time after installation. It is measured by cohort group - that is, based on when patients first opened the app. It is calculated as the ratio of the number of users active on a given period to the size of the cohort. This metric will be assessed throughout the observation until its end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User quitting attempts</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Number of quitting attempts per patient, including the frequency of the quitting attempts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User app behavior</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>It will be measured as the time spent per app section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User satisfaction with messages</measure>
    <time_frame>At 6 months after enrolment.</time_frame>
    <description>Patients' answers to a satisfaction questionnaire that will be handed to them at the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User message ratings</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>User's votes for each message in a 5 star scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User lifestyle feedback</measure>
    <time_frame>At enrollment and at 6 months after enrollment</time_frame>
    <description>Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaire EQ-5D-5L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User lifestyle feedback</measure>
    <time_frame>At enrollment and at 6 months after enrollment</time_frame>
    <description>Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaire IPAQ for physical activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>User lifestyle feedback</measure>
    <time_frame>At enrollment and at 6 months after enrollment</time_frame>
    <description>Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaires SF-36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The physical activity would be measured as the total time (minutes) of activity per user, retrieved by GoogleFit in the app.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Explore Successful Method to Quit Smoking</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Motivational message will be administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Motivational message will not be administrated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Case</intervention_name>
    <description>Motivational message will be administrated.</description>
    <arm_group_label>Case</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20 years or older and approach smoke cessation clinic at TMU hospital

          -  Have an Android mobile phone

          -  Able to read Traditional Chinese

          -  Willing to participate in all study components

          -  Willing to be followed-up for 6 months

          -  Smoked at least once every month in the last two years

          -  Current smoker

        Exclusion Criteria:

          -  â€¢ Below 20 years on the day of enrolment

               -  Not willing to participate in the study

               -  Those who do not have Android mobile phone or unable to read Mandarin

               -  Not willing to share medical information from EHR

               -  Subjects who develop adverse effects related to the pharmacological treatment
                  included in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Syed Abdul Shabbir, PhD</last_name>
    <phone>+886 227 36 1661</phone>
    <phone_ext>3340</phone_ext>
    <email>drshabbir@tmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Syed Abdul Shabbir</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Syed Abdul Shabbir, PhD</last_name>
      <phone>+886 266382736</phone>
      <phone_ext>1514</phone_ext>
      <email>drshabbir@tmu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Wei-Li Jeng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hao-Yi Fang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Tien Su, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Medical University</investigator_affiliation>
    <investigator_full_name>Shabbir Syed Abdul</investigator_full_name>
    <investigator_title>Assistant Professor &amp; Health IT Consultant</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

